Skip to main content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

An official website of the United States government
Grant Details

Grant Number: 1R03CA078195-01 Interpret this number
Primary Investigator: Fedi, Paolo
Organization: Mount Sinai School Of Medicine
Project Title: Validation of Erbb-3 Immunostaining in Breast Tumor
Fiscal Year: 1998


Abstract

DESCRIPTION (Applicant's Description) Evidence for biological synergism of plasma-membrane tyrosine kinase receptors erbB-3 and erbB-2 in model systems and human breast tumor cell lines raises the possibility that coexpression of these receptors may play a role in tumorigenesis and cell proliferation. Thus, identifying coexpressing erbB-2 and erbB-3 receptors in tumor specimens will provide greater specificity, and might identify a subpopulation of patients with different outcome and chemotherapeutic potential. However, the existing clinical studies are weak, and the data on expression of erbB-3 in breast tumors are inconsistent. In particular, the disagreement among studies with regard to cytoplasmic versus membrane staining is troubling. A major contributing factor is the poorly characterized antibody used in all studies. The goal of this proposal is to validate reagents for detection of erbB-3 expression by immunohistochemistry in paraffin sections of breast tumors. Therefore, our specific aims are: (1) to perform immunostaining of erbB-3 in transfected and tumor cell lines using five different erbB-3 antibodies, (2) to localize the cell fraction in which erbB-3 resides in these cell lines, and (3) to compare the pattern of staining of those antibodies in tumor specimens. Using this knowledge, we can establish a valid protocol for quantitating erbB-3 in breast cancer an evaluating its etiologic prognostic significance.



Publications


None

Back to Top